Which of the following is the Standard Short Oral Regimen for MDR/RR-TB treatment?

The Standard Short Oral Regimen for the treatment of Multidrug-resistant Tuberculosis (MDR-TB) and Rifampicin-resistant Tuberculosis (RR-TB) typically includes a combination of specific antibiotics that are effective against resistant strains of Mycobacterium tuberculosis. The regimen in option B is correct because it aligns with the recommended protocols that utilize newer medications and extended treatment durations to enhance treatment results and manage resistance effectively.

This regimen incorporates drugs such as Levofloxacin (Lfx) and Bedaquiline (Bdq), along with Clofazimine (Cfz), which are known to be part of the essential treatment strategies outlined by the World Health Organization (WHO) and other global health authorities for resistant TB. The inclusion of these specific medications within the timeline of 4-6 and a total treatment duration of 6 months reflects an international consensus aimed at improving efficacy and reducing the risk of further resistance development during therapy.

The other options present regimens that either do not conform to the updated guidelines for short regimens for MDR/RR-TB or include drug combinations that are less recommended in the current treatment landscape. Therefore, the option that includes Levofloxacin, Bedaquiline, and Clofazimine in the specified